
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Choosing Second-Line Therapy for Metastatic Kidney Cancer
Case Scenario 1: A 50-year old male with relapse of metastatic RCC
January 2014
April 2016
